Safety and Supply Issues from Consumers Point of View

  • B. O’Mahony
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 34)

Abstract

The attitude of people with haemophilia to blood and blood products and their perception of risk have been moulded by their experience in the past, by their current concerns, by the communication they receive and by the fact that they are long-term users of blood products. In the 1980’s, the haemophilia community was devastated by HIV infection. 40% of people with haemophilia in Western Europe were infected with HIV [1]. 60% of people with haemophilia were infected with Hepatitis B and 70% with Hepatitis C. The leading cause of death in people with haemophilia is AIDS followed by liver disease with bleeding coming a distant third. The average life expectancy of a man with severe haemophilia was 60 years in 1980 and by 1994 this had fallen to 42 years. The clinically serious sequelae of Hepatitis C have become more apparent in recent years [2].

Keywords

Blood Product Severe Haemophilia Viral Inactivation Maximal Safety Factor Viii Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    WFH Clearinghouse. HIV Infection/AIDS Surveys in Haemophilia. 1990–1995.Google Scholar
  2. 2.
    Lee CA. Hepatitis C Virus and Haemophilia: The National History of HCV in Hae-mophilic Patients. Haemophilia 1995;1 (Suppl. 4):8–12.Google Scholar
  3. 3.
    Evatt BL. CDC, Prions and haemophilia: Assessment of risk. Haemophilia 1998; 4:628–33.PubMedCrossRefGoogle Scholar
  4. 4.
    O’Mahony B. Product Withdrawal due to CJD risk in Ireland - Getting the information out. Symposium XXIII International Congress of the WFH, The Hague, May 1998.Google Scholar
  5. 5.
    Robillard L, et al. Key Issues in Haemophilia Treatment: Products and Care. WFH Facts & Figures: February 1997, No. 1.Google Scholar
  6. 6.
    Lloyd S. The Preparation of Single Donor Cryoprecipitate. WFH Facts & Figures, March 1997, No 2.Google Scholar
  7. 7.
    Peterson LP, Bird AR. Small Pool Heat Treated Intermediate Purity FVIII Concentrate WFH Facts & Figures, April 1997, No 3.Google Scholar
  8. 8.
    Teitel J. Viral Safety of Coagulation Factor-Concentrates. WFH Facts & Figures, December 1997, No 4.Google Scholar
  9. 9.
    O’Mahony B. Policy on Dissemination of Information on Problems with Factor Replacement Therapy. Memorandum to National Member Organisation of WFH. November 29, 1994.Google Scholar
  10. 10.
    EHC, Common Position on the Supply, Safety and Quality of Factor Concentrates. Adopted by EHC on November 16, 1997.Google Scholar
  11. 11.
    O’Mahony B. Irish Haemophilia Society Blood Product Policy. February 1996. IHS Dublin.Google Scholar
  12. 12.
    Hagan PJ. Blood Transfusion in Europe. A “White Paper” . Council of Europe Press 1993, p 31.Google Scholar
  13. 13.
    CPMP. Note for guidance for the assessment of efficacy and safety of Factor VIII and Factor IX products in clinical trials.Google Scholar
  14. 14.
    EAPPI. Response to 111/5769/94. Draft 5.Google Scholar
  15. 15.
    Combined Comments by members of the EPFA on Draft 5 (111/5769/94).Google Scholar
  16. 16.
    European Commission Decision on the use of specific risk material for transmissible spongiform encephalopathies (TSE). European Commission 97/534/EC, Luxemburg.Google Scholar
  17. 17.
    Directive 89/381/EEC. European Commission.Google Scholar
  18. 18.
    CPMP. Note for guidance for the assessment of efficacy and safety of Factor VIII and Factor EX products in clinical trials. European Commission 111/5769/94. Draft 5.Google Scholar
  19. 19.
    Colloquium on Blood Safety and Self Sufficiency. Adare, Co. Limerick, Ireland, 4–6 September 1996. Transfusion Today, 1996;29:3–6.Google Scholar
  20. 20.
    Schramm W, Etzler J. Status of HIV/HCV Financial Assistance Schemes in 73 WFH Member Countries. WFH, Montreal, October 1997.Google Scholar
  21. 20a.
    Schramm W, Etzler J. Status of HIV/HCV Financial Assistance Schemes in 73 WFH Member Countries. WFH, Montreal, October 1997.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1999

Authors and Affiliations

  • B. O’Mahony
    • 1
  1. 1.World Federation of HemophiliaMontrealCanada

Personalised recommendations